AwardAug 11, 2026, 09:06 AM
Longeveron Wins $1M XPRIZE Healthspan Milestone 2 Award
AI Summary
Longeveron Inc. announced its selection as a Milestone 2 Awardee in the XPRIZE Healthspan competition, securing a $1,000,000 award. This recognition is based on published clinical trial results showing its laromestrocel therapy increased 6-minute walk distance in patients with Aging-related Frailty. The company now has the opportunity to compete for the XPRIZE Grand Prize of up to $81,000,000, further advancing its stem cell therapy for life-threatening and chronic aging-related conditions.
Key Highlights
- Longeveron selected as Milestone 2 Awardee in XPRIZE Healthspan competition.
- Received $1,000,000 Milestone 2 Award for future clinical trial.
- Opportunity to compete for XPRIZE Grand Prize of up to $81,000,000.
- Laromestrocel increased 6-minute walk distance in Aging-related Frailty patients.
- Laromestrocel holds 52 issued patents worldwide.
- Laromestrocel has received five U.S. FDA designations for HLHS and Alzheimer's Disease.
Price Impact
More from LGVN